 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...197198199200201202203204205206207208209» |
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Mesylate Apatinib for Stage ? STS After Failure of Chemotherapy (clinicaltrials.gov) - Apr 20, 2017
P2, N=80, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1 trial: A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects (clinicaltrials.gov) - Apr 20, 2017
P1, N=20, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA (clinicaltrials.gov) - Apr 17, 2017
P2, N=66, Recruiting, Sponsor: China Medical University, China
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 14, 2017
P2, N=170, Not yet recruiting, Sponsor: First Affiliated Hospital of Guangxi Medical University
- ||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment change: Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) (clinicaltrials.gov) - Apr 13, 2017
P3, N=240, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=470 --> 240
- ||| AiTan (rivoceranib) / Elevar Therapeutics
Enrollment open: A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients (clinicaltrials.gov) - Apr 7, 2017
P1, N=76, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=470 --> 240 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, New trial, Metastases: Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=0, Approved for marketing, Sponsor: Peking University People's Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Monotherapy, Metastases: Apatinib for the Elderly Advanced Gastric Cancer (clinicaltrials.gov) - Apr 7, 2017
P2, N=60, Not yet recruiting, Sponsor: Affiliated Hospital of Qinghai University
- AiTan (rivoceranib) / HLB Bio Group
Trial primary completion date: Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Apr 6, 2017
P1, N=9, Recruiting, Sponsor: Peking University
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: SHR-1210-III-301-ESC: Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer (clinicaltrials.gov) - Apr 4, 2017
P3, N=438, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
New P3 trial: A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Apr 4, 2017
P3, N=120, Recruiting, Sponsor: Qingdao University
- | ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
Trial completion: Multiple Dose Study of SHR4640 in Healthy Subjects (clinicaltrials.gov) - Mar 30, 2017
P1, N=48, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers (clinicaltrials.gov) - Mar 30, 2017
P2, N=38, Not yet recruiting, Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- |||| Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
Trial completion: CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED) (clinicaltrials.gov) - Mar 29, 2017
P2, N=207, Completed, Sponsor: Novaliq GmbH
Recruiting --> Completed Active, not recruiting --> Completed
- |||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment open: A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation (clinicaltrials.gov) - Mar 29, 2017
P2, N=55, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC (clinicaltrials.gov) - Mar 28, 2017
P2, N=36, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Trial initiation date: Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer (clinicaltrials.gov) - Mar 24, 2017
P=N/A, N=20, Recruiting, Sponsor: Fujian Cancer Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Aug 2016
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer (clinicaltrials.gov) - Mar 22, 2017
P2, N=120, Recruiting, Sponsor: Hebei Medical University Fourth Hospital
- |||||||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P3 trial: Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) (clinicaltrials.gov) - Mar 16, 2017
P3, N=470, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, PD(L)-1 Biomarker: A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) (clinicaltrials.gov) - Mar 16, 2017
P2, N=118, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P3 trial: Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) (clinicaltrials.gov) - Mar 14, 2017
P3, N=240, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| AiTan (rivoceranib) / Elevar Therapeutics
New P1 trial: A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients (clinicaltrials.gov) - Mar 9, 2017
P1, N=76, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||| AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Metastases: ANGEL: A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer (clinicaltrials.gov) - Mar 8, 2017
P3, N=459, Recruiting, Sponsor: LSK BioPartners Inc.
Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Aug 2016 Not yet recruiting --> Recruiting
- AiTan (rivoceranib) / Elevar Therapeutics
Enrollment open: A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients (clinicaltrials.gov) - Mar 7, 2017
P1, N=24, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
Trial primary completion date: Multiple Dose Study of SHR4640 in Healthy Subjects (clinicaltrials.gov) - Feb 27, 2017
P1, N=48, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2016 --> Feb 2017
- | ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
Trial completion, Trial primary completion date: Single Dose Study of SHR4640 in Healthy Subjects (clinicaltrials.gov) - Feb 27, 2017
P1, N=50, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial primary completion date: Oct 2016 --> Feb 2017 Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Feb 2017
- ||| AiTan (rivoceranib) / HLB Bio Group
New trial: Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=80, Not yet recruiting, Sponsor: Jiangsu Cancer Institute & Hospital
- | AiTan (rivoceranib) / HLB Bio Group
Trial completion, Trial primary completion date: Effect of Rifampicin on the Pharmacokinetics of Apatinib (clinicaltrials.gov) - Feb 27, 2017
P1, N=20, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Feb 2017 Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Feb 2017
- | AiTan (rivoceranib) / HLB Bio Group
Trial completion, Trial primary completion date: Effect of Itraconazole on the Pharmacokinetics of Apatinib (clinicaltrials.gov) - Feb 27, 2017
P1, N=20, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Feb 2017 Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Feb 2017
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: A Phase II Study of Apatinib in STS Patients (clinicaltrials.gov) - Feb 27, 2017
P2, N=53, Not yet recruiting, Sponsor: Shanghai Jiao Tong University Affiliated Sixth People
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P1 trial: Food-Effect and Metabolism Study in Healthy Subjects (clinicaltrials.gov) - Feb 24, 2017
P1, N=16, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Enrollment change, Trial termination: SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer (clinicaltrials.gov) - Feb 23, 2017
P3, N=15, Terminated, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Feb 2017 N=574 --> 15 | Recruiting --> Terminated; difficulty in recruitment
- | AiTan (rivoceranib) / HLB Bio Group
Journal: A case report of targeted therapy with apatinib in a patient with advanced gastric cancer and high serum level of alpha-fetoprotein. (Pubmed Central) - Feb 19, 2017
N=574 --> 15 | Recruiting --> Terminated; difficulty in recruitment So, we speculate that maybe we can focus apatinib on serum AFP elevated GC patients.
- | AiTan (rivoceranib) / HLB Bio Group
Trial initiation date, Trial primary completion date: Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Feb 17, 2017
P2, N=48, Recruiting, Sponsor: Wuling Ou
So, we speculate that maybe we can focus apatinib on serum AFP elevated GC patients. Initiation date: Aug 2016 --> Nov 2016 | Trial primary completion date: May 2018 --> Nov 2017
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report. (Pubmed Central) - Feb 10, 2017
Our findings indicate that some cases of liposarcoma may be responsive to antiangiogenic agent apatinib. Randomized clinical studies are needed to further confirm the efficacy and safety of apatinib in the clinical treatment of liposarcoma.
- AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Trial primary completion date: A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies (clinicaltrials.gov) - Feb 10, 2017
P1, N=42, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Randomized clinical studies are needed to further confirm the efficacy and safety of apatinib in the clinical treatment of liposarcoma. Trial primary completion date: Sep 2016 --> Apr 2017
- AiTan (rivoceranib) / HLB Bio Group, Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
Enrollment open, Trial primary completion date: Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer (clinicaltrials.gov) - Feb 9, 2017
P2, N=40, Recruiting, Sponsor: Chinese Academy of Medical Sciences
Trial primary completion date: Sep 2016 --> Apr 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2017 --> Dec 2017
- NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
New trial: Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease (clinicaltrials.gov) - Feb 9, 2017
P=N/A, N=48, Recruiting, Sponsor: Novaliq GmbH
- || AiTan (rivoceranib) / HLB Bio Group
New P3 trial: PUMCH-NPLA81H-Ahead-T302: Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - Feb 9, 2017
P3, N=118, Recruiting, Sponsor: Peking Union Medical College Hospital
- AiTan (rivoceranib) / Elevar Therapeutics
New P2 trial: Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) (clinicaltrials.gov) - Feb 8, 2017
P2, N=30, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- |||||||||| AiTan (rivoceranib) / HLB Bio Group
New P3 trial, Metastases: ANGEL: A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer (clinicaltrials.gov) - Feb 2, 2017
P3, N=459, Not yet recruiting, Sponsor: LSK BioPartners Inc.
- AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Trial primary completion date, Metastases: A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment (clinicaltrials.gov) - Feb 1, 2017
P1, N=6, Recruiting, Sponsor: Bukwang Pharmaceutical
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2017 --> Dec 2017 Not yet recruiting --> Recruiting | Trial primary completion date: May 2016 --> Nov 2016
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA (clinicaltrials.gov) - Jan 26, 2017
P2, N=74, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- Opdivo (nivolumab) / Ono Pharma, BMS, plinabulin (BPI 2358) / BeyondSpring
Enrollment open, PD(L)-1 Biomarker: Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 23, 2017
P1/2, N=39, Recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting | Trial primary completion date: May 2016 --> Nov 2016 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / Elevar Therapeutics
New P1 trial: A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients (clinicaltrials.gov) - Jan 23, 2017
P1, N=24, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| Halaven (eribulin mesylate) / Eisai
New trial: IRENE: Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (clinicaltrials.gov) - Jan 23, 2017
P=N/A, N=400, Recruiting, Sponsor: Eisai GmbH
- AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer (clinicaltrials.gov) - Jan 23, 2017
P2, N=30, Recruiting, Sponsor: Third Military Medical University
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites (clinicaltrials.gov) - Jan 13, 2017
P2, N=120, Not yet recruiting, Sponsor: First Affiliated Hospital Bengbu Medical College
- AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Combination therapy, Surgery: The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer (clinicaltrials.gov) - Jan 4, 2017
P2, N=20, Recruiting, Sponsor: Chinese PLA General Hospital
- ||||| remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P2 trial: A Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy (clinicaltrials.gov) - Dec 27, 2016
P2, N=150, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.